Myeloma

Lenalidomide plus dexamethasone is a highly active regimen for newly diagnosed myeloma

Published in Blood Weekly, February 16th, 2006

Combination therapy, lenalidomide plus dexamethasone is reported to be a highly active regimen for newly diagnosed myeloma.

Scientists in the United States "report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/ Dex) as initial therapy for myeloma. Thirty-four patients were enrolled."

S.V. Rajkumar and colleagues, Mayo Clinic, wrote, "Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4,9 to 12, and 17 to 20 of each cycle.

"Objective response was defined as a decrease in serum monoclonal protein level by 50% or greater and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry